

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

**PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
AND RELEVANT RULES OF PROCEDURES**

CanSino Biologics Inc. (the “**Company**”) held the thirteenth meeting of the second session of the board of directors (the “**Board**”) of the Company on April 28, 2023, to consider and approve the proposals regarding the proposed amendments to the articles of association of the Company (the “**Articles of Association**”) and the relevant rules of procedures of the Company.

In view of the fact that the State Council of the PRC, the China Securities Regulatory Commission and The Stock Exchange of Hong Kong Limited published relevant laws, regulations and regulatory rules recently, in order to continue to comply with the regulatory requirements, according to the Company Law of the PRC, the Securities Law of the PRC, the Trial Measures for the Administration of Overseas Issuance and Listing of Securities by Domestic Enterprises, Guidelines for Articles of Association of Listed Companies (Revised in 2022), Guidelines for the Self-Regulation of Companies Listed on the Science and Technology Innovation Board of Shanghai Stock Exchange No. 1 – Standardized Operation (Shang Zheng Fa [2022] No. 14), the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the relevant laws, administrative regulations and listing rules of the Company’s listing place, taking into account the needs of the Company’s business development, the Company plans to revise the Articles of Association, and revise the Rules of Procedure of General Meeting and Rules of Procedure of Board of Directors and Rules of Procedure of Board of Supervisors (collectively, the “**Relevant Rules of Procedures**”) accordingly.

The proposed amendments to the Articles of Association and the proposed amendments to the Relevant Rules of Procedures are subject to the approval of the shareholders of the Company at a general meeting by way of special resolutions. A circular containing details of the proposed amendments to the Articles of Association and the proposed amendments to the Relevant Rules of Procedures will be despatched to the shareholders of the Company in due course.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, April 28, 2023

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.